8.17
Schlusskurs vom Vortag:
$7.86
Offen:
$7.82
24-Stunden-Volumen:
2.07M
Relative Volume:
0.99
Marktkapitalisierung:
$1.42B
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-2.9179
EPS:
-2.8
Netto-Cashflow:
$-304.44M
1W Leistung:
-2.16%
1M Leistung:
+6.38%
6M Leistung:
+125.07%
1J Leistung:
+78.77%
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RLAY
Relay Therapeutics Inc
|
8.17 | 1.36B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
What makes Relay Therapeutics Inc. stock attractive to growth funds2026 world cup usa national team round of 32 goalkeepers low block defense knockout prediction guide - Улправда
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week - MSN
Aug Action: What makes Relay Therapeutics Inc. stock attractive to growth fundsPortfolio Value Report & Weekly High Conviction Trade Ideas - moha.gov.vn
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Take Profit: Can Relay Therapeutics Inc. stock hit record highs again2025 Valuation Update & Precise Trade Entry Recommendations - moha.gov.vn
Will Relay Therapeutics Inc. stock gain from strong economyFibonacci Retracement Levels & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
Relay Therapeutics (NASDAQ:RLAY) Shares Up 4.9%Here's What Happened - MarketBeat
Congress Asset Management Co. Has $2.13 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics signals slowdown to recharge after busy year - Traders Union
Will Relay Therapeutics Inc stock pay special dividendsMarket Sentiment Report & Verified Technical Signals - moha.gov.vn
Zovegalisib’s Consistent Efficacy Across Tough Subgroups Could Be A Game Changer For Relay (RLAY) - simplywall.st
What sentiment indicators say about Relay Therapeutics Inc. stockQuarterly Market Summary & High Win Rate Trade Alerts - Улправда
Can Relay Therapeutics Inc. stock hit analyst price targets2025 Sector Review & AI Enhanced Trading Alerts - Улправда
Sectors Review: Is Relay Therapeutics Inc. stock a buy before product launchesJuly 2025 Decliners & Verified Entry Point Detection - Улправда
Why Relay Therapeutics Inc. stock could outperform in 2025Quarterly Portfolio Summary & Consistent Growth Stock Picks - Улправда
Is Relay Therapeutics Inc. stock a buy before product launchesJuly 2025 News Drivers & Low Drawdown Trading Strategies - Улправда
Is Relay Therapeutics Inc. stock attractive for passive investors2025 Biggest Moves & Risk Managed Investment Entry Signals - Улправда
Can Relay Therapeutics Inc. stock resist market sell offsPortfolio Return Report & Low Risk High Reward Ideas - DonanımHaber
Can Relay Therapeutics Inc. stock hit record highs againTake Profit & High Conviction Buy Zone Picks - DonanımHaber
How Relay Therapeutics Inc. stock reacts to oil pricesTrade Performance Summary & Daily Profit Focused Stock Screening - Улправда
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares - AOL.com
Alert from Equity-Insider.com was published in error and has been withdrawn - marketscreener.com
Relay Therapeutics (NASDAQ:RLAY) Trading Up 4.7%Here's What Happened - MarketBeat
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 - Yahoo Finance
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year HighStill a Buy? - MarketBeat
Bellevue Group AG Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics stock hits 52-week high at 8.62 USD By Investing.com - Investing.com Australia
Wells Fargo Upgrades Relay Therapeutics (RLAY) - Nasdaq
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug - Sahm
Why Is Relay Therapeutics Stock Gaining Friday?Relay Therapeutics (NASDAQ:RLAY) - Benzinga
RLAY Stock Receives Analyst Upgrade and Price Target Boost | RLA - GuruFocus
Relay Therapeutics stock hits 52-week high at 8.62 USD - Investing.com India
Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer - marketscreener.com
Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study - GuruFocus
Relay Therapeutics unveils efficacy subset analysis for zovegalisib at SABCS25 - Traders Union
Relay Therapeutics Reports Positive Efficacy Data for Zovegalisib in Metastatic Breast Cancer at SABCS 2025 - Quiver Quantitative
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 - Yahoo Finance
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
149,701 Shares in Relay Therapeutics, Inc. $RLAY Acquired by HighVista Strategies LLC - MarketBeat
Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy - MSN
Norges Bank Buys Shares of 835,874 Relay Therapeutics, Inc. $RLAY - MarketBeat
Diadema Partners LP Has $151,000 Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Mixed Investor Sentiment Surrounds Relay Therapeutics Stock - AD HOC NEWS
Growth Value: Why Relay Therapeutics Inc stock could outperform in 20252025 Market Trends & Technical Pattern Recognition Alerts - moha.gov.vn
JPMorgan Chase & Co. Reduces Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 5%What's Next? - MarketBeat
Relay Therapeutics, Inc. $RLAY Position Lifted by Franklin Resources Inc. - MarketBeat
Is Relay Therapeutics Inc. stock gaining market shareJuly 2025 Rallies & Low Drawdown Investment Strategies - Newser
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Oct 29 '25 |
Sale |
7.50 |
21,394 |
160,455 |
337,469 |
| Rahmer Peter | See remarks |
Oct 28 '25 |
Sale |
7.29 |
19,135 |
139,494 |
358,863 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 28 '25 |
Sale |
7.29 |
21,664 |
157,931 |
313,631 |
| Bergstrom Donald A | President, R&D |
Oct 28 '25 |
Sale |
7.29 |
30,897 |
225,239 |
521,823 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):